Anoro

Report
20 Pages
July 2018
Region: Global
Citeline
ID: 4775197

Drug Overview
GlaxoSmithKline and Theravance (now Innoviva) developed the once-daily inhaled combination, Anoro, consisting of umeclidinium and vilanterol for the treatment of chronic obstructive pulmonary disease (COPD). Umeclidinium is a long-acting muscarinic antagonist, while vilanterol is a long-acting beta 2 agonist. In December 2013, the US Food and Drug Administration approved Anoro as a maintenance therapy for the treatment of airflow obstruction in patients with COPD. In May 2014, the therapy received marketing authorization in the EU and was later approved in Japan in July 2014.

OVERVIEW

Drug Overview
Product Profiles
Anoro Ellipta: Chronic obstructive pulmonary disease (COPD)

LIST OF FIGURES

Figure 1: Anoro for COPD – SWOT analysis
Figure 2: The authors drug assessment summary of Anoro for COPD
Figure 3: The authors drug assessment summary of Anoro for COPD
Figure 4: Anoro sales for COPD across the US, Japan, and five major EU markets, by country, 2017–26

LIST OF TABLES

Table 1: Anoro drug profile
Table 2: Anoro Phase III data in COPD
Table 3: Anoro sales for COPD across the US, Japan, and five major EU markets, by country ($m), 2017–26

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€9691EUR$10,000USD£8,300GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€47487EUR$49,000USD£40,671GBP

Table of Contents

Related Topics

Related Reports

COPD in America 2023: Key Insights into Treatment Awareness & Satisfaction

COPD in America 2023: Understanding the COPD Patient Experience

Chronic Obstructive Pulmonary Disease (COPD) Treatment Global Market Report 2024

Anti-Asthmatics and COPD Drugs Global Market Report 2024

Chronic Obstructive Pulmonary Disease - Pipeline Insight, 2024